chronic hepatitis C chronic hepatitis C
Conditions
Interventions
Oral intake of Sovaldi 400mg once a day with Rebetol twice a day
600mg for those with body weight below 60kg, 800mg for those between 60 and 80kg, or 100mg for those over 80kg.
Sponsors
Tajiri Hitoshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who are visiting the department of Pediatrics or being admitted in our institute. 2. Patients with age 12 and 18 years at the agreement acquisition. 3. HCV genotype-2 infection. 4. Written informed consent after adequate explanation and acceptance.
Exclusion criteria
Exclusion criteria: 1. Patients with a suspicion of cirrhosis by blood examination or imaging studies. 2. Patients who is diagnosed as liver cirrhosis by pathological examination. 3. Patients with hepatocellular carcinoma. 4. Patients with poor adherence of medicine. 5. Patients who have any underlying disorders which can be affected by the treatment. 6. Patients who are assessed to be ineligible for this study by the principle investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negativity of HCVRNA at 4 week, 12 week, end of treatment(EOT), and 24 week after EOT. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) any side effects and their frequency, (2) effect on growth rate | — |
Contacts
Public ContactHitoshi Tajiri
Osaka General Medical Center
Outcome results
None listed